TDMS Study 05024-02 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
N-METHYLOLACRYLAMIDE
NTP Experiment-Test: 05024-02 Report: PEIRPT05
Study Type: CHRONIC Date: 09/04/94
Route: GAVAGE Time: 04:40:25
Facility: Battelle Columbus Laboratory
Chemical CAS #: 924-42-5
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05024-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC N-METHYLOLACRYLAMIDE Date: 09/04/94
Route: GAVAGE Time: 04:40:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 25 MG/KG 50 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50
Early Deaths
Dead 5 9 10
Moribund 3 6 6
Accident 1
Survivors
Terminal Sacrifice 41 35 33
Missing 1
Animals Examined Microscopically 50 50 49
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (45) (4) (39)
Intestine Large, Cecum (46) (5) (42)
Leiomyoma 1 (20%)
Intestine Large, Rectum (46) (6) (43)
Intestine Small, Duodenum (44) (5) (41)
Intestine Small, Ileum (44) (4) (43)
Intestine Small, Jejunum (45) (4) (42)
Liver (50) (50) (49)
Adenocarcinoma, Metastatic, Mammary Gland 1 (2%)
Hemangioma, Multiple 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%)
Hemangiosarcoma, Metastatic, Skin 1 (2%)
Hepatocellular Carcinoma 3 (6%) 3 (6%) 2 (4%)
Hepatocellular Adenoma 2 (4%) 3 (6%) 15 (31%)
Hepatocellular Adenoma, Multiple 1 (2%) 1 (2%) 2 (4%)
Mesentery (48) (6) (47)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hemangiosarcoma 1 (2%)
Pancreas (50) (6) (47)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Salivary Glands (50) (7) (47)
Stomach, Forestomach (46) (6) (44)
Squamous Cell Papilloma 2 (5%)
Tongue (1)
Squamous Cell Papilloma 1 (100%)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 05024-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC N-METHYLOLACRYLAMIDE Date: 09/04/94
Route: GAVAGE Time: 04:40:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 25 MG/KG 50 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (6) (49)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (17%) 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (50) (6) (47)
Capsule, Carcinoma 1 (2%)
Adrenal Gland, Medulla (50) (7) (48)
Pheochromocytoma Benign 1 (14%)
Islets, Pancreatic (50) (6) (47)
Pituitary Gland (49) (14) (43)
Pars Distalis, Adenoma 12 (24%) 5 (36%) 4 (9%)
Pars Distalis, Adenoma, Multiple 1 (2%)
Pars Intermedia, Adenoma 1 (2%)
Pars Intermedia, Carcinoma 1 (2%) 1 (2%)
Thyroid Gland (48) (6) (48)
Bilateral, Follicular Cell, Adenoma, Multiple 1 (2%)
Follicular Cell, Adenoma 3 (6%) 3 (6%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (1)
Adenocarcinoma 1 (100%)
Ovary (50) (45) (47)
Granulosa Cell Tumor Benign 5 (11%) 5 (11%)
Uterus (50) (35) (49)
Hemangioma 1 (3%)
Hemangiosarcoma 1 (2%) 1 (3%)
Leiomyoma 1 (3%)
Polyp Stromal 2 (4%) 1 (3%)
Vagina (1) (2)
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 05024-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC N-METHYLOLACRYLAMIDE Date: 09/04/94
Route: GAVAGE Time: 04:40:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 25 MG/KG 50 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (6) (48)
Femoral, Hemangiosarcoma 1 (2%)
Vertebral, Hemangiosarcoma 1 (2%)
Lymph Node (50) (13) (46)
Mediastinal, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (8%)
Mediastinal, Hepatocellular Carcinoma,
Metastatic, Liver 1 (2%)
Lymph Node, Mesenteric (11) (7) (13)
Spleen (50) (19) (48)
Hemangiosarcoma 1 (2%)
Hemangiosarcoma, Metastatic, Skin 1 (5%)
Thymus (48) (4) (38)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (29) (48) (33)
Adenoacanthoma 1 (2%) 1 (3%)
Adenocarcinoma 1 (3%) 1 (3%)
Adenoma 2 (7%) 4 (8%)
Fibroadenoma 1 (3%)
Skin (50) (14) (48)
Sebaceous Gland, Adenoma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 2 (4%) 2 (14%) 4 (8%)
Subcutaneous Tissue, Fibrosarcoma, Multiple 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 3 (21%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (50) (6) (48)
Fibrosarcoma, Metastatic, Skin 1 (2%) 1 (17%) 2 (4%)
Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (7) (48)
Carcinoma, Metastatic, Pituitary Gland 1 (2%)
Meningioma Benign 1 (2%)
Peripheral Nerve (47) (43) (42)
Spinal Cord (50) (6) (49)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05024-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC N-METHYLOLACRYLAMIDE Date: 09/04/94
Route: GAVAGE Time: 04:40:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 25 MG/KG 50 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (49)
Adenoacanthoma, Metastatic, Mammary Gland 1 (2%)
Adenocarcinoma, Metastatic, Mammary Gland 1 (2%)
Alveolar/Bronchiolar Adenoma 4 (8%) 3 (6%) 6 (12%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 2 (4%) 4 (8%) 7 (14%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%)
Basosquamous Tumor Malignant 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hemangiosarcoma, Metastatic, Skin 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 1 (2%) 1 (2%)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%)
Mediastinum, Hemangiosarcoma 1 (2%)
Nose (50) (6) (48)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (47) (45) (48)
Adenoma 5 (11%) 6 (13%) 12 (25%)
Adenoma, Multiple 1 (2%) 1 (2%)
Carcinoma 3 (7%) 2 (4%)
Bilateral, Adenoma 1 (2%) 7 (15%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (11) (48)
Urinary Bladder (43) (6) (47)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(49)
Lymphoma Malignant 1 (2%)
Lymphoma Malignant Histiocytic 5 (10%) 2 (4%) 6 (12%)
Lymphoma Malignant Lymphocytic 7 (14%) 7 (14%) 8 (16%)
Lymphoma Malignant Mixed 4 (8%) 1 (2%) 9 (18%)
Lymphoma Malignant Undifferentiated Cell 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05024-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC N-METHYLOLACRYLAMIDE Date: 09/04/94
Route: GAVAGE Time: 04:40:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 25 MG/KG 50 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 33 41 47
Total Primary Neoplasms 66 67 108
Total Animals with Benign Neoplasms 24 24 39
Total Benign Neoplasms 36 35 61
Total Animals with Malignant Neoplasms 24 26 33
Total Malignant Neoplasms 30 32 47
Total Animals with Metastatic Neoplasms 2 7 5
Total Metastatic Neoplasm 5 9 9
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05024-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC N-METHYLOLACRYLAMIDE Date: 09/04/94
Route: GAVAGE Time: 04:40:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 25 MG/KG 50 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50
Early Deaths
Moribund 12 14 10
Dead 8 16 19
Survivors
Terminal Sacrifice 29 20 20
Moribund 1
Dead 1
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (50) (20) (48)
Gallbladder (44) (12) (33)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (3%)
Intestine Small, Duodenum (45) (16) (40)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (3%)
Polyp Adenomatous 1 (2%)
Intestine Small, Jejunum (45) (16) (40)
Adenocarcinoma 1 (6%)
Liver (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Hemangiosarcoma 2 (4%)
Hepatocellular Carcinoma 3 (6%) 7 (14%) 10 (20%)
Hepatocellular Carcinoma, Multiple 3 (6%) 6 (12%) 2 (4%)
Hepatocellular Adenoma 3 (6%) 3 (6%) 13 (26%)
Hepatocellular Adenoma, Multiple 5 (10%) 1 (2%) 6 (12%)
Mesentery (43) (18) (49)
Adenocarcinoma, Metastatic, Stomach 1 (6%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Pancreas (49) (21) (47)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Salivary Glands (49) (20) (50)
Stomach, Forestomach (50) (49) (48)
Mast Cell Tumor Benign 1 (2%)
Squamous Cell Papilloma 1 (2%) 2 (4%)
Stomach, Glandular (50) (20) (45)
Adenocarcinoma 1 (5%)
Page 7
NTP Experiment-Test: 05024-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC N-METHYLOLACRYLAMIDE Date: 09/04/94
Route: GAVAGE Time: 04:40:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 25 MG/KG 50 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (20) (50)
Adenocarcinoma, Metastatic, Stomach 1 (5%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 2 (4%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (48) (21) (48)
Capsule, Adenoma 1 (2%)
Capsule, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%)
Adrenal Gland, Medulla (48) (20) (50)
Pheochromocytoma Benign 1 (2%) 1 (5%) 2 (4%)
Bilateral, Pheochromocytoma Benign 1 (2%) 1 (2%)
Islets, Pancreatic (50) (19) (47)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Pituitary Gland (48) (14) (42)
Pars Distalis, Adenoma 1 (7%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (50) (20) (49)
Follicular Cell, Adenoma 1 (5%) 2 (4%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ductus Deferens (23) (16) (28)
Epididymis (50) (20) (50)
Prostate (49) (20) (50)
Seminal Vesicle (29) (18) (36)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (3%)
Testes (50) (20) (50)
Adenocarcinoma, Metastatic, Stomach 1 (5%)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05024-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC N-METHYLOLACRYLAMIDE Date: 09/04/94
Route: GAVAGE Time: 04:40:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 25 MG/KG 50 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Blood (3) (2)
Bone Marrow (50) (20) (50)
Femoral, Adenocarcinoma, Metastatic, Stomach 1 (5%)
Lymph Node (49) (32) (50)
Axillary, Fibrosarcoma, Metastatic, Skin 1 (2%)
Bronchial, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%)
Mediastinal, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%)
Mediastinal, Mandibular,
Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%)
Lymph Node, Mesenteric (19) (17) (24)
Mediastinal, Adenocarcinoma, Metastatic,
Stomach 1 (6%)
Spleen (50) (26) (50)
Hemangiosarcoma 2 (4%)
Thymus (36) (13) (39)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 3 (8%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (33) (50)
Adenocarcinoma, Metastatic, Stomach 1 (3%)
Basal Cell Adenoma 1 (2%)
Subcutaneous Tissue, Fibroma 4 (8%) 3 (6%)
Subcutaneous Tissue, Fibrosarcoma 13 (26%) 14 (42%) 10 (20%)
Subcutaneous Tissue, Fibrosarcoma, Multiple 2 (4%) 1 (3%) 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (34) (50)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Skeletal Muscle (50) (24) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Fibrosarcoma, Metastatic, Skin 3 (6%) 7 (29%) 3 (6%)
Diaphragm, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%)
____________________________________________________________________________________________________________________________________
Page 9
NTP Experiment-Test: 05024-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC N-METHYLOLACRYLAMIDE Date: 09/04/94
Route: GAVAGE Time: 04:40:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 25 MG/KG 50 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (20) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Meningioma Benign 1 (5%)
Spinal Cord (48) (20) (49)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (49) (50) (50)
Adenocarcinoma, Metastatic, Stomach 1 (2%)
Alveolar/Bronchiolar Adenoma 3 (6%) 6 (12%) 10 (20%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma 2 (4%) 3 (6%) 9 (18%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%) 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%) 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (4%) 2 (4%) 1 (2%)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 2 (4%)
Nose (50) (20) (50)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (48) (49) (50)
Adenoma 1 (2%) 13 (27%) 27 (54%)
Carcinoma 1 (2%) 2 (4%)
Bilateral, Adenoma 1 (2%) 2 (4%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (22) (50)
Adenocarcinoma, Metastatic, Stomach 1 (5%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 2 (4%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Urethra (30) (8) (35)
Urinary Bladder (49) (21) (49)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Page 10
NTP Experiment-Test: 05024-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC N-METHYLOLACRYLAMIDE Date: 09/04/94
Route: GAVAGE Time: 04:40:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 25 MG/KG 50 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50)
Lymphoma Malignant 1 (2%)
Lymphoma Malignant Histiocytic 6 (12%) 3 (6%) 2 (4%)
Lymphoma Malignant Lymphocytic 2 (4%) 4 (8%)
Lymphoma Malignant Mixed 3 (6%) 2 (4%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 11
NTP Experiment-Test: 05024-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC N-METHYLOLACRYLAMIDE Date: 09/04/94
Route: GAVAGE Time: 04:40:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 25 MG/KG 50 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 35 39 47
Total Primary Neoplasms 54 71 116
Total Animals with Benign Neoplasms 16 22 38
Total Benign Neoplasms 22 29 70
Total Animals with Malignant Neoplasms 28 33 35
Total Malignant Neoplasms 32 42 46
Total Animals with Metastatic Neoplasms 5 10 9
Total Metastatic Neoplasm 6 18 33
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 12
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------
--multipart-boundary
Content-type: text/plain
Range: bytes 71780-71780/71780
--multipart-boundary--